Rosalind Advisors Inc. Cuts Stake in Xeris Biopharma Holdings, Inc. $XERS

Rosalind Advisors Inc. lessened its stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 16.7% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,795,766 shares of the company’s stock after selling 359,828 shares during the quarter. Xeris Biopharma accounts for about 5.1% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 6th biggest holding. Rosalind Advisors Inc.’s holdings in Xeris Biopharma were worth $14,618,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently made changes to their positions in the company. Royal Bank of Canada raised its holdings in shares of Xeris Biopharma by 1,411.2% during the first quarter. Royal Bank of Canada now owns 213,084 shares of the company’s stock worth $1,170,000 after acquiring an additional 198,984 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Xeris Biopharma by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 83,982 shares of the company’s stock worth $461,000 after purchasing an additional 3,594 shares during the period. Millennium Management LLC boosted its stake in Xeris Biopharma by 19.0% in the 1st quarter. Millennium Management LLC now owns 2,317,972 shares of the company’s stock worth $12,726,000 after purchasing an additional 369,420 shares during the period. Goldman Sachs Group Inc. increased its holdings in Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock worth $15,317,000 after purchasing an additional 1,199,435 shares in the last quarter. Finally, Caxton Associates LLP bought a new position in Xeris Biopharma during the 1st quarter worth about $170,000. Institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Trading Down 4.4%

Xeris Biopharma stock opened at $5.48 on Friday. The firm has a 50-day moving average of $6.94 and a 200-day moving average of $7.53. Xeris Biopharma Holdings, Inc. has a one year low of $3.81 and a one year high of $10.08. The company has a debt-to-equity ratio of 16.10, a current ratio of 2.19 and a quick ratio of 1.57. The company has a market cap of $944.92 million, a price-to-earnings ratio of -547.45 and a beta of 0.61.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Monday, March 2nd. The company reported $0.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. Xeris Biopharma had a negative return on equity of 5.33% and a net margin of 0.19%.The business had revenue of $85.81 million for the quarter, compared to the consensus estimate of $86.00 million. On average, equities analysts expect that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Xeris Biopharma news, insider John Patrick Shannon, Jr. sold 24,907 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $7.08, for a total value of $176,341.56. Following the completion of the transaction, the insider directly owned 2,705,346 shares in the company, valued at $19,153,849.68. This trade represents a 0.91% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Beth Hecht sold 16,667 shares of the business’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $7.43, for a total value of $123,835.81. Following the transaction, the insider directly owned 1,308,103 shares in the company, valued at $9,719,205.29. This trade represents a 1.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 225,308 shares of company stock valued at $1,626,103 in the last ninety days. 6.47% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of brokerages have recently commented on XERS. Weiss Ratings upgraded Xeris Biopharma from a “sell (d-)” rating to a “hold (c-)” rating in a report on Wednesday, March 4th. Barclays initiated coverage on Xeris Biopharma in a report on Monday, December 8th. They set an “overweight” rating and a $9.00 price objective for the company. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Xeris Biopharma in a research note on Monday, March 2nd. Finally, Wall Street Zen raised Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 7th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Xeris Biopharma Profile

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.